Latest news

• Genfit scraps phase 3 trial of experimental NASH drug

  Another potential competitor – Intercept Pharmaceuticals – is still awaiting an FDA review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again in

• Boehringer bolsters NASH pipeline with Enleofen link-up

  It is already approved for primary biliary cholangitis (PBC) under the Ocaliva trade name.

• Genfit presses the gas on NASH with combo trials

  moment. It’s notable that Gilead now has a two disappointing late-stage trial readouts for its ASK1 inhibitor selonsertib in NASH, while front-runner Intercept is pitching its candidate Ocaliva

• Gilead's NASH drug fails again

  The company seen as closest to this goal is Intercept, which recently presented further data backing up its case for Ocaliva in NASH. ... Three times as many patients on the higher 25mg dose of Ocaliva in the REGENERATE study saw an improvement of two

• Gilead drives NASH development with insitro collaboration

  The chances of that being a Gilead candidate is overshadowed by Intercept’s recent FDA filing of its own NASH candidate Ocaliva, although that drug is making investors nervous with its